Unaudited financial (Consolidated and Standalone)results for the quarter ended 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech reported consolidated Q2 FY26 revenue of ₹3,774.98 lakhs, up roughly 25% from ₹3,015.99 lakhs in Q2 FY25. For the half year, consolidated revenue rose about 8% to ₹6,790.97 lakhs from ₹6,268.65 lakhs. On the profit front, the company swung back to a consolidated profit after tax of ₹106.87 lakhs in H1 FY26, compared with a loss of ₹610.75 lakhs in H1 FY25 — a clear turnaround driven by subsidiaries. Standalone numbers were weaker, with H1 FY26 PAT at ₹59.60 lakhs versus ₹64.63 lakhs a year ago. Operating cash flow was negative on both bases (standalone -₹1,011.84 lakhs, consolidated -₹1,017.20 lakhs), reflecting higher working capital needs. Statutory auditors Venkatesh & Co issued an unmodified (clean) review opinion.
Short-term positive from the revenue rebound and consolidated return to profit, but negative operating cash flows and a slight dip in standalone earnings temper the picture. The director resignation appears routine and the BSE fine for delayed compliance officer appointment (already paid) is a minor governance flag rather than a material issue.